Outcome With the Repositionable and Retrievable Boston Scientific Lotus Valve Compared With the Balloon-Expandable Edwards Sapien 3 Valve in Patients Undergoing Transfemoral Aortic Valve Replacement [Structural Heart Disease]
Conclusions—
Transfemoral aortic valve replacement with the ES3 and the Lotus were associated with similar 30-day, 12-month, and 24-month clinical outcomes. Need for permanent pacemaker implantation was significantly higher with the repositionable Lotus device.
Clinical Trial Registration—
URL: http://www.clinicaltrials.gov. Unique identifier: NCT02162069.
Source: Circulation: Cardiovascular Interventions - Category: Cardiology Authors: Seeger, J., Gonska, B., Rottbauer, W., Wohrle, J. Tags: Aortic Valve Replacement/Transcatheter Aortic Valve Implantation Structural Heart Disease Source Type: research
More News: Academia | Cardiology | Cardiovascular | Clinical Trials | Heart | Heart Disease | Heart Valve Surgery | Stroke